| 曹明,张帆.人类表皮生长因子受体-2在乳腺癌研究中进展[J].安徽医药,2015,19(12):2263-2266. |
| 人类表皮生长因子受体-2在乳腺癌研究中进展 |
| Current development of human epidermal growth factor receptor-2 in breast cancer research |
| 投稿时间：2015-04-17 |
| DOI： |
| 中文关键词: 人类表皮生长因子受体-2(HER-2) 乳腺癌 HER-2检测 |
| 英文关键词: human epidermal growth factor receptor-2 breast cancer HER-2 testing |
| 基金项目: |
|
| 摘要点击次数: 2759 |
| 全文下载次数: 246 |
| 中文摘要: |
| 人类表皮生长因子受体-2(human epidermal growth factor receptor-2,HER-2)是乳腺癌诊治过程中重要的预后指标和HER-2靶向药物的治疗指标。乳腺癌患者中约30%会出现HER-2的过表达,HER-2检测的目的就是鉴别出那些可以从HER-2靶向治疗中获益的人群。目前靶向治疗药物包括赫赛、拉帕替尼和T-DM1等。这些治疗可以大大提高HER-2阳性浸润性乳腺癌患者的生存期。所以选择适当的检测标准准确判读HER-2状态是乳腺癌患者预后判断以及制定有效治疗方案的先决条件,对乳腺癌的诊疗具有积极的指导作用。 |
| 英文摘要: |
| Human epidermal growth factor receptor-2(HER-2)is an important prognostic predictor and key predictor of anti-HER-2 therapy of breast cancer.About 30% of breast cancer patients will have HER-2 over expression.The purpose of HER-2 testing is to identify patients who can benefit from the HER-2 targeted therapy. Currently targeted medicines include trastuzumab(Herceptin),lapatinib (Lapatinib), T-DM1 and the like.These treatments can greatly improve the survival of HER-2-positive invasive breast cancer patients.So choosing the appropriate testing standards and accurate testing of HER-2 status is a prerequisite for making a prognosis and developing effective treatment programs,which is important in clinical practice.The current development of human epidermal growth factor receptor-2 in breast cancer research will be reviewed in this paper. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
